Literature DB >> 8911138

Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help.

C Fayolle1, U M Abdel-Motal, L Berg, E Deriaud, M Jondal, C Leclerc.   

Abstract

In several experimental models, synthetic peptides were shown to activate efficiently cytotoxic T-lymphocyte (CTL) responses and therefore represent an attractive strategy to develop new vaccines. However, the mechanisms by which they induce CTL responses are not yet fully understood. Several studies using 15 16-mer peptides previously demonstrated that CD4 helper T cells are required to induce optimal CTL responses with synthetic peptides. However, recently it was suggested that shorter 8 12-mer peptides could have an increased in vivo immunogenicity. In the present study, we therefore investigated if such optimal-length peptides still require CD4+ T-cell help to activate CTL responses. To address this question three synthetic peptides containing different viral CTL epitopes were injected into mice depleted of CD4+ or CD8+ T cells using specific monoclonal antibodies or into mice genetically deficient in those T-cell populations. Our results clearly established that activation of CTL responses by those short optimal peptides does not require CD4+ T-cell help and therefore suggested that high-density binding of peptides to major histocompatibility complex class I molecules on the surface of antigen-presenting cells is required for direct activation of CD8+ T cells, independently of CD4+ T-cell help.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911138      PMCID: PMC1456654          DOI: 10.1046/j.1365-2567.1996.d01-704.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

Authors:  W M Kast; R Offringa; P J Peters; A C Voordouw; R H Meloen; A J van der Eb; C J Melief
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

2.  In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides.

Authors:  X Zhou; L Berg; U M Motal; M Jondal
Journal:  J Immunol Methods       Date:  1992-08-30       Impact factor: 2.303

3.  In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help.

Authors:  C Fayolle; E Deriaud; C Leclerc
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

4.  Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.

Authors:  M L De Bruijn; T N Schumacher; J D Nieland; H L Ploegh; W M Kast; C J Melief
Journal:  Eur J Immunol       Date:  1991-12       Impact factor: 5.532

5.  Priming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides.

Authors:  X M Gao; B Zheng; F Y Liew; S Brett; J Tite
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

6.  Impaired generation of anti-viral cytotoxicity against lymphocytic choriomeningitis and vaccinia virus in mice treated with CD4-specific monoclonal antibody.

Authors:  T P Leist; M Kohler; R M Zinkernagel
Journal:  Scand J Immunol       Date:  1989-12       Impact factor: 3.487

7.  Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule.

Authors:  P Romero; G Eberl; J L Casanova; A S Cordey; C Widmann; I F Luescher; G Corradin; J L Maryanski
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

8.  Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells.

Authors:  R M Buller; K L Holmes; A Hügin; T N Frederickson; H C Morse
Journal:  Nature       Date:  1987 Jul 2-8       Impact factor: 49.962

9.  In vivo priming of cytotoxic T lymphocyte responses in relation to in vitro up-regulation of major histocompatibility complex class I molecules by short synthetic peptides.

Authors:  X Zhou; U M Abdel Motal; L Berg; M Jondal
Journal:  Eur J Immunol       Date:  1992-12       Impact factor: 5.532

10.  Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4.

Authors:  A Rahemtulla; W P Fung-Leung; M W Schilham; T M Kündig; S R Sambhara; A Narendran; A Arabian; A Wakeham; C J Paige; R M Zinkernagel
Journal:  Nature       Date:  1991-09-12       Impact factor: 49.962

View more
  3 in total

1.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.

Authors:  Laetitia Fend; Christelle Remy-Ziller; Johann Foloppe; Juliette Kempf; Sandrine Cochin; Luc Barraud; Nathalie Accart; Philippe Erbs; Sylvie Fournel; Xavier Préville
Journal:  Oncoimmunology       Date:  2015-10-06       Impact factor: 8.110

Review 3.  Peptide Vaccine: Progress and Challenges.

Authors:  Weidang Li; Medha D Joshi; Smita Singhania; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Vaccines (Basel)       Date:  2014-07-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.